Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02937246
Other study ID # 4-2015-1147
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date May 31, 2016
Est. completion date December 2019

Study information

Verified date June 2019
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous studies indicated that covered stents are less likely to become occluded in comparison to bare stents. While the probability of occlusions caused by tumor in-growth is less in covered stents, they are more likely to spontaneously migrate to a position that is distal to the original deployment site. However, newer covered stents with improved designs, such as the partially covered double bare metallic stent used for this study, include features to mitigate the migration issue. The purpose of this study is to confirm whether the difference in patency rate between regular covered stents and bare stents, which has already been well established by existing studies, is also reproducible when double covered stents are compared against double bare stents.


Description:

Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, GB cancer, and pancreatic cancer. In biliary stricture by malignancy, biliary drainage with placement of self-expanding metal stent (SEMS) for palliation is the therapy of choice in these patients. When compared to plastic stents, SEMS present a significantly decreased risk of recurrent biliary obstruction. SEMS are also more cost-effective than plastic stents in patients with a life expectancy of longer than 4 months. However, despite their numerous benefits, SEMS become occluded in up to 50 % of patients in the first 6-8 months. In order to minimize the occurrence of this issue, covered stents were developed. Previous studies indicated that covered stents are less likely to become occluded in comparison to bare stents. While the probability of occlusions caused by tumor in-growth is less in covered stents, they are more likely to spontaneously migrate to a position that is distal to the original deployment site. However, newer covered stents with improved designs, such as the partially covered double bare metallic stent used for this study, include features to mitigate the migration issue. The purpose of this study is to confirm whether the difference in patency rate between regular covered stents and bare stents, which has already been well established by existing studies, is also reproducible when double covered stents are compared against double bare stents.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 260
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Pathologically confirmed malignant biliary obstruction or clinically defined malignant biliary obstruction

- malignant biliary obstruction was located more than 1cm from the hilum

- older than 20 years old

- Life expectancy > 6 months

- Inoperable case due to advanced stage or comorbidity

- Informed consent obtained

Exclusion Criteria:

- Inadequate case for ERCP

- Failed endoscopic approach to duodenum or biliary tract

- biliary obstruction was located at hilum or IHD

- patients with uncontrolled infection

- Pregnancy

- No signed informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SEMS(self-expandable metallic stent)
Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
Stenting by ERCP (endoscopic retrograde cholangiopancreatography)


Locations

Country Name City State
Korea, Republic of Severance Hospital, Yonsei University Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean duration of stent patency Check the duration until the date of obstruction of inserted stent within 6 months after stenting 6 months after stenting
Secondary Patency rate of stent 6 months after stenting
Secondary Overall survival 6 months after stenting
See also
  Status Clinical Trial Phase
Recruiting NCT04691349 - CAR-T for r/r Malignant Tumors in Children Early Phase 1
Recruiting NCT04672473 - Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine Phase 1/Phase 2
Recruiting NCT06080984 - The Application of Novel Oncolytic Virus in Late Stage Solid Tumors Phase 1
Recruiting NCT04991506 - A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02552004 - Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study N/A
Recruiting NCT05280873 - Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP Phase 1
Completed NCT06093945 - Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects Phase 1
Completed NCT05592262 - Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects Phase 1
Completed NCT03012945 - Epidural Anesthesia-analgesia and Long-term Outcome N/A
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT06084767 - 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer N/A
Completed NCT03354741 - Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children N/A
Recruiting NCT03931720 - Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor Phase 1/Phase 2
Completed NCT01906632 - Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy N/A
Recruiting NCT05596344 - Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
Active, not recruiting NCT04230200 - Prospective Screening Programme for Malignant Tumors
Completed NCT04952766 - Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Phase 4
Completed NCT04730843 - A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05781555 - A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors N/A
Completed NCT01884168 - Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy